Drug Database
CL

cloricromene (cloricromene / Proendotal / Cromocap)

✓ Approved

Fidia · PTAFR · 小分子

什么是 cloricromene?

cloricromene 是一种小分子,由Fidia研发。该药已获批,用于治疗相关适应症,给药途径:Unknown。

药物档案

商品名cloricromene, Proendotal, Cromocap
公司Fidia
药物类别小分子
分子靶点PTAFR
给药途径Unknown
状态Approved

作用机制

分子靶点

cloricromene 作用于 1 个分子靶点:

PTAFRplatelet activating factor receptor (PAFR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

cloricromene 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersPeripheral vascular disorder✓ Approved
Vascular disordersThrombosis✓ Approved

相关研究文献

PubMedNaunyn-Schmiedeberg's archives of pharmacology2026-11-13

Correction: Cloricromene, a coumarine derivative, reduced the development of periodontitis in rats.

Muià Carmelo C, Mazzon Emanuela E, Zito Daniele D, Maiere Daniele D et al.

PMID 43024076
阅读全文 →
PubMedBritish journal of pharmacology2024-11-18

RETRACTION: Cloricromene, a Coumarine Derivative, Protects Against Collagen-induced Arthritis in Lewis Rats.

PMID 39552043
阅读全文 →
PubMedInvestigative ophthalmology & visual science2009-03-13

Protective effects of a coumarin derivative in diabetic rats.

Bucolo Claudio C, Ward Keith W KW, Mazzon Emanuela E, Cuzzocrea Salvatore S et al.

Retinal microvascular cells play a crucial role in the pathogenesis of diabetic retinopathy. The endothelial effects of cloricromene, a novel coumarin derivative, on diabetic retinopathy induced by streptozotocin (STZ) in the rat were investigated. Cloricromene (10 mg/kg intraperitoneally) was administered daily in diabetic rats, and 60 days later eyes were enucleated for localization of nitrotyrosine, ICAM-1, VEGF, ZO-1, occludin, claudin-5, and VE-cadherin by immunohistochemical analysis. The effect of treatment was also evaluated by TNFalpha, ICAM-1, VEGF, and eNOS protein levels measurement in the retina with the respective ELISA kits. Blood-retinal barrier (BRB) integrity was also evaluated by Evans blue. Increased amounts of cytokines, adhesion molecule, and nitric oxide synthase were observed in retina. Cloricromene treatment significantly lowered retinal TNFalpha, ICAM-1, VEGF, and eNOS. Furthermore, immunohistochemical analysis for VEGF, ICAM-1, nitrotyrosine (a marker of peroxynitrite), and tight junctions revealed positive staining in the retina from STZ-treated rats. The degree of staining for VEGF, ICAM-1, nitrotyrosine, and tight junctions was markedly reduced in tissue sections obtained from diabetic rats treated with cloricromene. Treatment with cloricromene suppressed diabetes-related BRB breakdown by 45%. This study provides the first evidence that the new coumarin derivative cloricromene attenuates the degree of inflammation preserving the BRB in diabetic rats.

PMID 19279317
阅读全文 →
PubMedJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics2007-06-27

Retinal and systemic pharmacokinetics of the anti-inflammatory drug cloricromene following oral administration in the rat and rabbit.

Bucolo Claudio C, Maugeri Francesco F, Maltese Adriana A, Ward Keith W KW

The aim of this study was to evaluate the retina and plasma distribution of cloricromene, a coumarin derivative, and its active metabolite (MET) after an oral administration in rabbits and rats. A single dose of cloricromene was orally administered to rabbits (10 or 100 mg/kg) and to rats (100 mg/kg). Retina and plasma samples were collected at 15, 30, 60, and 90 min following administration. Drug concentrations in the retina and plasma were measured by high-performance liquid chromatography. As anticipated, only the active metabolite was found in all samples. The retina and plasma showed the same T(max); peak levels of the drug were achieved at 15 min in rats and at 30 min in rabbits. In rabbits, MET exposure was approximately dose-proportional in both retina and plasma between the 10- and 100-mg/kg dose. Substantial retinal exposure was observed in both the rat and rabbit, at exposures approximately nine- to sixteenfold lower in the retina than in plasma. The results showed that the active metabolite of cloricromene reached the retina after a single oral dose with exposures proportional to those in plasma. These data, along with the previously published potency data for cloricromene, suggest that cloricromene could be potentially useful in ischemic-retinal diseases where amelioration of blood flow and inflammation is desirable.

PMID 17593009
阅读全文 →
PubMedThe Journal of pharmacy and pharmacology2006-06-30

Enhancement of availability of cloricromene at brain level by a lipophilic prodrug.

Pignatello R R, Maltese A A, Maugeri F F, Bucolo C C

The pharmacokinetics of a lipophilic alkylamino acid (LAA) prodrug of cloricromene (AD6), name CLOR-C4, was studied in rat plasma and brain. In particular, we observed that the intraperitoneal administration of CLOR-C4 to rats was able to provide a slight but statistically significant higher concentration of the active drug metabolite (cloricromene acid) in the brain compared with the parent drug administered by the same way. The correlation between pharmacokinetic data and calculated partition (LogP) and brain distribution coefficients (LogBB) supported the hypothesis that the amphiphilic nature of the LAA promoiety could be responsible for a better penetration into the brain, more than the simple increase of lipophilicity gained with respect to the parent drug.

PMID 16805962
阅读全文 →
PubMedAAPS PharmSciTech2006-04-06

Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene.

Pignatello Rosario R, Ricupero Nadia N, Bucolo Claudio C, Maugeri Francesco F et al.

The purpose of this study was to improve the stability of cloricromene (AD6) in ophthalmic formulations and its drug availability at the ocular level. To this end, AD6-loaded polymeric nanoparticle suspensions were made using inert polymer resins (Eudragit RS100 and RL100). We modified the quasi-emulsion solvent diffusion technique by varying some formulation parameters (the drug-to-polymer ratio, the total drug and polymer amount, and the stirring speed). The chemical stability of AD6 in the nanosuspensions was assessed by preparing some formulations using (unbuffered) isotonic saline or a pH 7 phosphate buffer solution as the dispersing medium. The formulations were stored at 4 degrees C, and the rate of degradation of AD6 was followed by high performance liquid chromatography (HPLC). The obtained nanosuspensions showed mean sizes and a positive surface charge (zeta-potential) that make them suitable for an ophthalmic application; these properties were maintained upon storage at 4 degrees C for several months. In vitro dissolution tests confirmed a modified release of the drug from the polymer matrixes. Nanosuspensions prepared with saline solution and no or lower amounts of surfactant (Tween 80) showed an enhanced stability of the ester drug for several months, with respect to an AD6 aqueous solution. Based on the technological results, AD6-loaded Eudragit Retard nanoparticle suspensions appear to offer promise as a means to improving the shelf life and bioavailability of this drug after ophthalmic application.

PMID 16584158
阅读全文 →

注册免费账户还可查看另外 55 篇文献

免费注册查看全部文献 →

了解更多cloricromene